Member Info for Bazzaman

Wow, BOL enjoy your beer, you've earned it.

Up up & away 74.75

today at 74.25 GLA

On Tuesday should be good. GLA

Fair value is at least 80p & break up value in excess of 100p but whether we get there on the back of the results I'm not sure. More likely towards the spring somewhere between the 2 values. BOL

Ahead of the long anticipated results check out the brokers estimates against y/e 2014 which are as follows; Revenue up from £39.8m to est £98.0m +146%, PbT up from £8.6m to est £15m +74% & EPS up from 2.87p to est 6.1p. Dividend is expected to be hiked 50% from 0.6p to 0.9p per share. It will be interesting to see whether these estimates are met or indeed exceeded. GLA.

On or before 19th October, so Monday looks likely.

http://www.investorschronicle.co.uk/2015/10/13/comment/simon-thompson/cleaning-up-2InbS278JaFfUVPvA6YPoM/article.html

Will be updating their price target at mid-day today so will be interesting to see whether that brings any more buyers. GLA.

Tristel, a developer of infection control products based its own proprietary chlorine dioxide (Clo2) chemistry (>75% sales). Its wipes, foams, gels, liquids and surface disinfectants are considered to be the 'gold standard' in the UK for decontaminating small medical instruments in out-patient departments and for surface cleaning in hospitals. Today the company has posted like-for-like top line growth of 13.8% to £15.3m for the 12 months ending June 2015 (FY15) - driven by the launch of innovative new products, greater adoption in the UK and excellent growth abroad. Better still, we think that this momentum is set to continue, and may actually accelerate as more customers realise the benefits of switching to Clo2 technology. Last year foreign markets generated 35.9% of group turnover - climbing sequentially from 32.5% in H1 to 39.1% in H2, reflecting strong demand across most of Tristel's international footprint of 38 countries. In aggregate, we anticipate total revenues will motor along at a 15% pa clip for the foreseeable future, Tristel has logical ambitions regarding the vast US market, but even if the FDA there were to thwart their application, we still think this science rich stock represents good value at 107p, trading on an underlying PEG ratio of only 1.0x that is 45% below the peer group average. In fact, not only is the stock good value on an absolute basis versus our upgraded price target of 135p/share (from 110p), but it is also cheap relative to the wider healthcare ecosystem - trading below peer group averages with regards to EV/sales, EV/EBITA and PE multiples, despite offering much better prospects.

Bullish ahead of Monday's results http://www.investorschronicle.co.uk/2015/10/07/comment/simon-thompson/cleaning-up-with-superbug-buster-g5RND3qRsh1dNgSlNvXpdO/article.html GLA.

Upgraded to a buy. http://www.investorschronicle.co.uk/2015/10/06/comment/simon-thompson/engineering-ratings-upgrades-j8sPhazWUxlkeoS2w3Ei4I/article.html

Check with your broker but payment has to be completed by 11am on 19th October.

After ex-rights price was 223.55 so a close of 230 was an increase of 6.45 (2.89%) so a positive view to take up your rights issue IMHO. GLA

You're welcome, me too. BOL.

Trading flat at ex-rights issue price which took effect today.

A nice article on rights issue using ETO attached which is easy to follow. http://www.sharescope.co.uk/philoakley_article45.jsp

International industrial fastenings group, Trifast (TR), is extending its European presence through the acquisition of industrial distributor Kuhlmann Befestigungselemente, which is based in Germany. The total consideration is £6.16m. The initial amount of £4.9m was paid on completion and the remainder will be deferred for 12 months and is to serve as a retention against which any potential warranty and indemnity claims will be offset. TR says it will be will be investing into Kuhlmann to further develop the opportunities in the German market and expects the acquisition to be earnings enhancing in the first full year. Germany is the fourth largest industrial fastener market globally and the biggest in Europe. Over the last five years TR has successfully developed its export business and last year sales into Germany contributed around £7m. Trifast's chief executive, Mark Belton, added: "This is a very positive step for both TR and Kuhlmann and we welcome everyone into the Trifast family. Having already built a close trading relationship between our two businesses and respective management teams, we are now establishing a strong local presence and a base for what we see as an exciting opportunity for both TR and Kuhlmann."

Well done.

Gossip on Twitter suggests results & some Corporate activity tomorrow according to the share chat on ADVFN. BOL.